Comparison of insulin aspart and lispro: Pharmacokinetic and metabolic effects

Diabetes Care

Volumn 26, Issue 7, 2003, Pages 2027-2031

  Homko, Carol ^a   Deluzio, Antonio ^a   Jimenez, Carolyn ^a   Kolaczynski, Jerzy W ^a   Boden, Guenther ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; INSULIN LISPRO; ANTIDIABETIC AGENT; C PEPTIDE; DRUG DERIVATIVE; INSULIN, ASP(B28)-;

ADULT; ARTICLE; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LIPID METABOLISM; MALE; BLOOD; BODY MASS; CALORIMETRY; DRUG EFFECT; GLUCOSE TOLERANCE TEST; METABOLISM;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; CALORIMETRY, INDIRECT; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE;

EID: 1542787613     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.7.2027     Document Type: Article

References (20)

1. Home PD, Lindholm A, Hylleberg B, Round P: Improved glycemic control with insulin aspart. Diabetes Care 21:1904-1909, 1998
2. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L: Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 23: 583-588, 2000
3. Feinglos Thacker CH, English J, Bethel MA, Lane JD: Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 20:1539-1542, 1997
4. Anderson JH Jr, Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, DiMarchi R: Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment: Multicenter Insulin Lispro Study Group. Diabetes 46:265-270, 1997
5. Boden G, DeSantis R, Chen X, Morris M, Badoza F: Glucose metabolism and leg blood flow after pancreas/kidney transplantation. J Clin Endocrinol Metab 76: 1229-1233, 1993
6. Wolfe RR: Tracers in metabolic research. In Radioisotope and Stable Isotope/Mass Spectrometry Methods. New York, Alan R. Liss, 1984, p. 261
7. Steele R, Wall JS, DeBodo RC, Altszuler N: Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187:15-24, 1956
8. Owen OE, Trapp VE, Reichard GA Jr, Mozzoli MA, Smith R, Boden G: Effects of therapy of the nature and quantity of fuels oxidized during diabetic ketoacidosis. Diabetes 29:365-372, 1980
9. Tappy L, Owen OE, Boden G: Effect of hyperinsulinemia on urea pool size and substrate oxidation rates. Diabetes 37: 1212-1216, 1988
10. Lukaski HC: Methods for the assessment of human body composition: traditional and new. Am J Clin Nutr 46:537-556, 1997
11. Hedman CA, Lindstrom T, Arnqvist HJ: Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care 24: 1120-1121, 2001
12. Plank J, Wutte A, Brunner G, Siebenhofer A, Semlitsch B, Sommer R, Hirschberger S, Peiber TR: A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 25: 2053-2057, 2002
13. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J: Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 76:149-155, 1985
14. Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J: Uptake and release of glucose by the human kidney: postabsorptive rates and responses to epinephrine. J Clin Invest 96:2528-2533, 1995
15. Bondonna RC, Groop LC, Zych K, Shank M, DeFronzo RA: Dose-dependent effect of insulin on plasma free fatty acid turn-over and oxidation in humans. Am J Physiol 259:E736-E750, 1990
16. Torlone E, Pampanelli S, Lalli C, Del Sindaco P, DiVincenzo A, Rambotti AM, Modarelli F, Epifano L, Kassi G, Perriello G, Brunetti P, Bolli G: Effects of the short-acting insulin analog [Lys(B28), Pro (B29)] on postprandial blood glucose control in IDDM. Diabetes Care 19:945-952, 1996
17. Jacobs MAJM, Keulen ETP, Kanc K, Casteleijn S, Scheffer P, Deville W, Heine RJ: Metabolic efficacy of preprandial administration of Lys (B28), Pro (B29) human insulin analog in IDDM patients. Diabetes Care 20:1279-1289, 1997
18. Home PD, Barriocanal L, Lindholm A: Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in health individuals. Eur J Clin Pharmacol 55:199-203, 1999
19. Home P, Lindholm A, Riis A: Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 17:762-770, 2000
20. Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, Madsbad S: Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 37:41-46, 2000